231 related articles for article (PubMed ID: 32132142)
1. The Changing Landscape of Fabry Disease.
Svarstad E; Marti HP
Clin J Am Soc Nephrol; 2020 Apr; 15(4):569-576. PubMed ID: 32132142
[No Abstract] [Full Text] [Related]
2. Genetics and Gene Therapy of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
[TBL] [Abstract][Full Text] [Related]
3. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
[TBL] [Abstract][Full Text] [Related]
4. [Renal involvement in Fabry's disease: diagnosis, follow-up and enzyme replacement therapy].
Mignani R; Feriozzi S; Carraro G; Martinelli F; Cianciaruso B
G Ital Nefrol; 2009; 26(5):577-84. PubMed ID: 19802803
[TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications.
Mignani R; Cagnoli L
J Nephrol; 2004; 17(3):354-63. PubMed ID: 15365954
[TBL] [Abstract][Full Text] [Related]
6. Paradoxical Response to Enzyme Replacement Therapy of Fabry Disease Cardiomyopathy.
Frustaci A; Russo MA; Chimenti C
Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27486136
[No Abstract] [Full Text] [Related]
7. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
[TBL] [Abstract][Full Text] [Related]
8. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?
Waldek S; Feriozzi S
BMC Nephrol; 2014 May; 15():72. PubMed ID: 24886109
[TBL] [Abstract][Full Text] [Related]
9. Stroke and Chronic Kidney Disease in Fabry Disease.
Tapia D; Kimonis V
J Stroke Cerebrovasc Dis; 2021 Sep; 30(9):105423. PubMed ID: 33160817
[TBL] [Abstract][Full Text] [Related]
10. Renal complications of Fabry disease.
Basic-Jukic N; Kes P; Coric M; Basic-Kes V
Curr Pharm Des; 2013; 19(33):6046-50. PubMed ID: 23448456
[TBL] [Abstract][Full Text] [Related]
11. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
Schiffmann R; Hughes DA; Linthorst GE; Ortiz A; Svarstad E; Warnock DG; West ML; Wanner C;
Kidney Int; 2017 Feb; 91(2):284-293. PubMed ID: 27998644
[TBL] [Abstract][Full Text] [Related]
12. [Anderson-Fabry's disease: diagnostic problems, therapeutic relevance, and clinical experience in the treatment of the disease with enzyme replacement therapy in nephropathic patients].
Cianciaruso B; Pisani A; Andreucci MV; Parente N; Andria G; Federico S; Sabbatini M; Sessa A
G Ital Nefrol; 2003; 20(2):113-9. PubMed ID: 12746795
[TBL] [Abstract][Full Text] [Related]
13. Renal complications of Fabry disease in children.
Najafian B; Mauer M; Hopkin RJ; Svarstad E
Pediatr Nephrol; 2013 May; 28(5):679-87. PubMed ID: 22898981
[TBL] [Abstract][Full Text] [Related]
14. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.
Germain DP; Charrow J; Desnick RJ; Guffon N; Kempf J; Lachmann RH; Lemay R; Linthorst GE; Packman S; Scott CR; Waldek S; Warnock DG; Weinreb NJ; Wilcox WR
J Med Genet; 2015 May; 52(5):353-8. PubMed ID: 25795794
[TBL] [Abstract][Full Text] [Related]
15. Fabry's disease--a comprehensive review on pathogenesis, diagnosis and treatment.
Mahmud HM
J Pak Med Assoc; 2014 Feb; 64(2):189-94. PubMed ID: 24640811
[TBL] [Abstract][Full Text] [Related]
16. [Neurological manifestations of Fabry disease].
Mendióroz M; Fernández-Cadenas I; Montaner J
Rev Neurol; 2006 Dec 16-31; 43(12):739-45. PubMed ID: 17160925
[TBL] [Abstract][Full Text] [Related]
17. Kidney transplantation from a mother with unrecognized Fabry disease to her son with low α-galactosidase A activity: A 14-year follow-up without enzyme replacement therapy.
Odani K; Okumi M; Honda K; Ishida H; Tanabe K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():57-9. PubMed ID: 26971403
[TBL] [Abstract][Full Text] [Related]
18. Uneventful pregnancy outcome after enzyme replacement therapy with agalsidase beta in a heterozygous female with Fabry disease: A case report.
Germain DP; Bruneval P; Tran TC; Balouet P; Richalet B; Benistan K
Eur J Med Genet; 2010; 53(2):111-2. PubMed ID: 20045092
[TBL] [Abstract][Full Text] [Related]
19. Anderson-Fabry disease in Austria.
Lorenz M; Hauser AC; Püspök-Schwarz M; Kotanko P; Arias I; Zodl H; Kramar R; Paschke E; Voigtländer T; Sunder-Plassmann G
Wien Klin Wochenschr; 2003 Apr; 115(7-8):235-40. PubMed ID: 12778775
[TBL] [Abstract][Full Text] [Related]
20. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations.
Oqvist B; Brenner BM; Oliveira JP; Ortiz A; Schaefer R; Svarstad E; Wanner C; Zhang K; Warnock DG
Nephrol Dial Transplant; 2009 Jun; 24(6):1736-43. PubMed ID: 19293136
[No Abstract] [Full Text] [Related]
[Next] [New Search]
